Clinical Trials

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04644289 2025-10-03

WoO

Phase 2 Recruiting

60 enrolled

Carcinoma, Ovarian Epithelial

NCT04532645 2025-09-23

OVAL-1

Completed

342 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

BreastGastrointestinalGenitourinaryGynecologic

298 enrolled 18 charts

Ovarian

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Ovarian Neoplasms

NCT03534453 2025-07-10

L-MOCA

229 enrolled

Ovarian Neoplasms

NCT06686030 2025-04-16

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Phase 2 Recruiting

150 enrolled

Platinum-sensitive Ovarian Cancer

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

Triple Negative Metastatic Breast Cancer

NCT04330040 2025-03-10

SOLI

Phase 4 Completed

202 enrolled 15 charts

Breast Neoplasms, Ovarian Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 2 FDA

Phase 3 Active not recruiting

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03737643 2025-01-29

DUO-O

1,407 enrolled 3 FDA

Ovarian Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

70 enrolled 13 charts

Breast Neoplasms, Ovarian Neoplasms

NCT05700669 2024-09-19

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Phase 1/2 Completed

3 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03402841 2024-08-21

OPINION

279 enrolled 17 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1/2 Terminated

7 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1 Terminated

24 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

98 enrolled

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT04669002 2023-08-02

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

34 enrolled

Ovarian Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

99 enrolled 17 charts

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03106987 2022-10-07

OReO

220 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02476968 2022-09-10

ORZORA

Phase 4 Completed

181 enrolled 24 charts

BRCA or HRR+ Mutated Ovarian Cancer Patients

NCT02282020 2022-07-26

SOLO3

266 enrolled 31 charts

Ovarian Neoplasms

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

62 enrolled 15 charts

Ovarian Neoplasms

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

BreastGastrointestinalGenitourinaryGynecologicLymphoid

49 enrolled

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04239014 2021-03-10

DUETTE

Phase 2 Withdrawn

Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

97 enrolled 22 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

58 enrolled 13 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03063710 2018-05-17

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

No longer available

PSR Ovarian Cancer With a BRCA Mutation

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Approved for marketing

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

NCT02392676 2016-05-02

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Phase 3 Withdrawn